Tirzepatide, a new class in medications, is being investigated for obesity treatment. Tirzepatide triggers the body’s receptors to GIP (glucose dependent insulinotropic polypeptide), and GLP-1 (glucagon like peptide-1) receptor activators, and is administered once a week.
Semaglutide, also a GLP-1 activater, is the most recent FDA-approved weight loss medication. It has been available for some time and has proven to be a great option for weight loss. Semaglutide has had incredible results for many patients at Transform You. Tirzepatide is the new kid on campus. These are the details.
TIRZEPATIDE STUDIES
The New England Journal of Medicine recently reported on a trial that used Tirzepatide to treat obesity and excess weight in adults who were not diabetic. Participants saw significant and sustained weight loss after receiving a Tirzepatide injection once per week. The study group saw a 85% to 91% drop in weight compared to the 35% who lost weight in the placebo. Half of those in the 10-mg Tirzepatide and 57% in the 15-mg groups lost more than 20%. The Tirzepatide groups also showed improved metabolic and cardiovascular measures.
Patients on 5-mg tirzepatide experienced an average weight loss of 16% in the phase 3 SURMOUNT-1 study. Patients on the 10-mg dose saw an average weight loss of 21.4%, or about 49 pounds. Patients on the 15 mg dose experienced an average weight loss rate of 22.5%, or about 52 pounds.
The FDA approved the dual GIP/GLP-1 receptor antagonist Tirzepatide in May 2022. Eli Lilly announced that it will soon be available in US pharmacies. Eli Lilly now allows Tirzepatide’s option to be expanded as a weight loss medication. The presentation was made at the American Diabetes Association’s 82nd Scientific Sessions. It praised Tirzepatide for its ability to treat obesity and diabetes.
Jeff Emmick (Vice President of Product Development at Lilly Diabetes) stated that “Tirzepatide” was the first investigational medicine that delivered more than 20% weight loss in a phase 3. This affirms our confidence in its ability to help people with obesity. Obesity is a chronic condition that requires effective treatment.
Tirzepatide’s Weight Loss Benefits
Clinical trials have shown that patients who use Tirzepatide might experience:
- Substantial A1C cuts
- Weight loss is increasing
- Improvements in cardiometabolic measurements
- Higher levels of triglycerides
- Appetite decrease
- Lower blood pressure
- Increased insulin sensitivity
This article was written by a peptide professional from Domestic Peptides. Looking to Buy DMAA? Well, look no further. Welcome to Domestic Peptides where you’ll find a huge selection of Research Peptides for sale and Research Chemicals for Sale, all made in the USA.
Huffpost Health Blog 